Meeting
2023 ASCO Annual Meeting
Association of immune-related adverse events and efficacy outcomes in phase II trial of consolidation nivolumab plus ipilimumab or nivolumab alone after chemoradiation in patients with unresectable stage III non–small-cell lung cancer (NSCLC).
Authors
Cynthia Wei
Indiana University School of Medicine, Indianapolis, IN
Cynthia Wei , Sandra K. Althouse , Hirva Mamdani , Nasser H. Hanna , Greg Andrew Durm
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8565)
DOI
10.1200/JCO.2023.41.16_suppl.8565
Abstract #
8565
Poster Bd #
192
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Analysis of circulating tumor DNA in the phase 2 BTCRC LUN 16-081 trial of consolidation nivolumab with or without ipilimumab after chemoradiation in stage III non–small cell lung cancer.
First Author: Soyeong Jun
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase II trial of consolidation nivolumab or nivolumab plus ipilimumab following concurrent chemoradiation in unresectable stage III NSCLC: BTCRC LUN16-081.
First Author: Greg Andrew Durm
Poster
2022 ASCO Annual Meeting
Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16-081.
First Author: Greg Andrew Durm
Poster
2022 ASCO Annual Meeting
Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC.
First Author: Jarushka Naidoo